Status:
COMPLETED
Effects of Red Ginseng on Gastrointestinal Symptoms and Microbiota After Surgery for Gastrointestinal Cancer
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Stomach Cancer
Pancreatobiliary Cancer
Eligibility:
All Genders
19-79 years
Phase:
NA
Brief Summary
After surgery for gastrointestinal cancer (stomach cancer, pancreaticobiliary cancer, colorectal cancer), many patients experiences various symptoms such as weight loss, diarrhea, constipation and exc...
Eligibility Criteria
Inclusion
- Pathologically diagnosed with gastrointestinal cancers (stomach cancer, pancreatobiliary cancer, colorectal cancer) prior to surgery.
- Clinically staged and anticipated to not receive adjuvant chemotherapy after surgery.
- Eligible for complete surgical resection (R0 resection).
- ASA (American Society of Anesthesiologists) score of 3 or below.
- Intereseted in health functional foods.
- Not consumed probiotics or prebiotics for at least three months prior to study enrollment.
- Willing to refrain from consuming additional probiotics or prebiotics during the study period, apart from the provided red ginseng tablets.
Exclusion
- Patients aged 80 years or older.
- Patients who received neoadjuvant therapy before surgery.
- Patients with underlying gastrointestinal disorders (e.g., inflammatory bowel disease, ulcerative colitis, Crohn's disease, galactose intolerance, lactase deficiency, glucose-galactose malabsorption, short bowel syndrome, other hereditary gastrointestinal diseases, and autoimmune diseases).
- Patients unable to orally consume red ginseng tablets.
- Patients with a history of previous abdominal organ surgery, radiation therapy, or chemotherapy.
- Patients with intestinal obstruction before surgery.
- Patients regularly taking probiotic or prebiotic supplements.
- Patients requiring formation of an ileostomy after surgery.
- Patients with uncontrolled diabetes that may affect gastrointestinal function.
- Patients with underlying conditions such as liver failure or renal failure.
- Patients allergic to red ginseng.
- Patients who received more than two weeks of antibiotic treatment during hospitalization.
Key Trial Info
Start Date :
June 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 14 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06561516
Start Date
June 14 2022
End Date
July 14 2023
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severacne Hospital Yonsei University College of Medicine
Seoul, South Korea